Clinical Cardiology Alert – March 1, 2024
March 1, 2024
View Issues
-
Does Anyone with Severe Aortic Stenosis Not Benefit from TAVR?
A single-center, retrospective study of low-flow low-gradient aortic stenosis patients has shown that a gradient < 20 mmHg identifies a high-risk group because of significant comorbidities that may not benefit from transcutaneous aortic valve replacement.
-
Do Patients Feel Better After Tricuspid Valve Clipping?
A further analysis of the quality-of-life parameters in a trial of tricuspid transcatheter edge-to-edge repair (T-TEER) in patients with severe symptomatic tricuspid regurgitation vs. medical therapy alone has shown that T-TEER is associated with significant benefits in physical functioning and quality of life that are sustained for one year and were proportional to the magnitude of regurgitation reduction.
-
PFO Closure Review Shows High Proportion of Off-Label Use
In this retrospective cohort study using administrative data from a U.S. payor source, only 58.6% of patients undergoing patent foramen ovale closure had the procedure done for the approved indication of stroke or systemic embolism. A significant proportion of patients were outside the recommended age range.
-
Long-Term Antiplatelet Therapy After PCI
The five-year follow-up of patients randomized to clopidogrel vs. aspirin monotherapy beyond one year after percutaneous coronary intervention has shown that clopidogrel is noninferior, but not superior, to aspirin for preventing the combined endpoint of adverse cardiovascular or major bleeding events.
-
Effect of Atrial Fibrillation Catheter Ablation on Psychological Well-Being
A randomized trial of catheter ablation vs. medical therapy for atrial fibrillation (AF) patients has shown that anxiety and depression scores are significantly reduced by catheter ablation and are associated with decreases in AF burden and improved physical symptoms.